Get the Stockscreener App
103.30
0.06%
0.0594
Exact Sciences Corp stock is traded at $103.30, with a volume of 1.21M.
It is up +0.06% in the last 24 hours and up +0.85% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$103.24
Open:
$103.2
24h Volume:
1.21M
Relative Volume:
0.24
Market Cap:
$19.61B
Revenue:
$3.08B
Net Income/Loss:
$-986.58M
P/E Ratio:
-19.43
EPS:
-5.3172
Net Cash Flow:
$292.08M
1W Performance:
-0.05%
1M Performance:
+0.85%
6M Performance:
+126.54%
1Y Performance:
+109.50%
1-Day Range:
$103.14
$103.41
1-Week Range:
$103.14
$103.50
52-Week Range:
$38.81
$103.54
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.28 | 19.61B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
502.88 | 189.66B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.78 | 150.27B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.38 | 50.25B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
123.83 | 35.58B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
317.39 | 31.72B | 3.17B | 642.63M | 539.81M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - MSN
Exact Sciences Faces Rising Operational Risk and Strategic Constraints Amid Pending Abbott Merger - TipRanks
Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% - TradingView
Exact Sciences misses Q4 expectations for earnings, beats for revenue - Wisconsin State Journal
Illinois Municipal Retirement Fund Boosts Stake in Exact Sciences Corporation $EXAS - MarketBeat
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Exact Sciences: Fourth Quarter Earnings Overview - Bitget
Exact Sciences: Q4 Earnings Snapshot - kens5.com
Exact Sciences (EXAS) Surpasses Q4 Revenue Expectations - GuruFocus
Exact Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Corp. Reports Record Fourth Quarter and Full Year 2025 Results - TradingView
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer - Yahoo Finance
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewswire Inc.
Alger Mid Cap 40 ETF Q4 2025 Portfolio Update - Seeking Alpha
Exact Sciences Corporation (NASDAQ:EXAS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Take Profit: Will Exact Sciences Corporation benefit from green energy policiesLayoff News & Technical Buy Zone Confirmation - baoquankhu1.vn
Aug PreEarnings: Will Exact Sciences Corporation outperform its industry peersQuarterly Market Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS - MarketBeat
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Magazine
Exact Sciences (NASDAQ:EXAS) Sets New 12-Month HighTime to Buy? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (NasdaqNFBK), Coterra Energy Inc. (NYSECTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – - ChartMill
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Exact Sciences Milestone In Breast Cancer Genomics And What It Means For EXAS - Yahoo Finance
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test - Law360
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent - The AI Journal
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop? - AD HOC NEWS
Principal Financial Group Inc. Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
C WorldWide Group Holding A S Has $46.97 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS Shares Sold by Heritage Investors Management Corp - MarketBeat
Medicare coverage pathway established for multi-cancer detection tests By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Applauds Medicare Coverage Pathway for Can - GuruFocus
Medicare coverage pathway established for multi-cancer detection tests - Investing.com
Exact Sciences welcomes Medicare coverage pathway for multi-cancer tests - StreetInsider
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests - Business Wire
Exact Sciences (NASDAQ:EXAS) Hits New 12-Month HighShould You Buy? - MarketBeat
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Pa - GuruFocus
Exact Sciences stock hits 52-week high at $102.69 - Investing.com
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide - Business Wire
Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 - Insider Monkey
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Bear Alert: Is Exact Sciences Corporation showing insider buyingWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal - Yahoo Finance UK
Freedom Capital Markets upgrades Abbott Labs stock rating to Buy on Exact Sciences deal - Investing.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement - Insider Monkey
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exact Sciences Corp Stock (EXAS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
66,487 |
| Condella Sarah | EVP, Human Resources |
Dec 23 '25 |
Option Exercise |
0.00 |
47,208 |
0 |
118,059 |
| Herriott James | SVP, General Counsel & Sec |
Dec 23 '25 |
Option Exercise |
0.00 |
33,780 |
0 |
32,934 |
| Bloomer Aaron | EVP, Chief Financial Officer |
Dec 23 '25 |
Option Exercise |
0.00 |
63,099 |
0 |
59,571 |
| ORVILLE JACOB A | EVP, GM, Screening |
Nov 19 '25 |
Sale |
75.00 |
5,000 |
375,000 |
23,237 |
| Herriott James | SVP, General Counsel & Sec |
Nov 19 '25 |
Sale |
70.00 |
1,000 |
70,000 |
11,585 |
4.81%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):